热门资讯> 正文
葛兰素史克宣布下一代低碳Ventolin舒喘宁吸入器的第三阶段数据将温室气体排放量减少92%
2025-10-22 16:09
- Data confirm therapeutic equivalence and comparable safety profile for Ventolin (salbutamol) containing innovative low carbon propellant
- Approximately 300 million salbutamol MDIs are sold globally every year1,2
- If approved, this next-generation low carbon salbutamol has the potential to reduce greenhouse gas emissions by 92%3 per inhaler
- GSK will proceed with regulatory submissions, with launch expected from 2026
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。